(Total Views: 364)
Posted On: 02/19/2018 8:49:58 PM
Post# of 72446
First NEW class of antibiotics since 1987. What is that worth -- especially since the anti-inflammatory properties may be even more important?
First p53-modulating drug, possible able to work on half of all cancers. What is something like that worth if it works alone (monotherapy)? Or, if it needs to be used in combination with other drugs?
The only thing it could even be slightly reasonable to try to quantify for value is Prurisol, and we can't do that because we don't know what the efficacy is and therefore what the prospective market would be.
In other words, there isn't any way to value this company at the moment, except to say that any one of these drugs for any one of the indications for which there have been clinical trials would be worth a LOT more than the current market cap.
First p53-modulating drug, possible able to work on half of all cancers. What is something like that worth if it works alone (monotherapy)? Or, if it needs to be used in combination with other drugs?
The only thing it could even be slightly reasonable to try to quantify for value is Prurisol, and we can't do that because we don't know what the efficacy is and therefore what the prospective market would be.
In other words, there isn't any way to value this company at the moment, except to say that any one of these drugs for any one of the indications for which there have been clinical trials would be worth a LOT more than the current market cap.
(5)
(0)
